Oregano and basil leaves for people with unstable angina
Official title: Effects of Increasing Polyphenol Intake by Consumption of Oregano and Basil Leaves on Plasma Inflammatory and Lipid Factors and Total Urinary Polyphenol in Patients With Unstable Angina
Run by Shahid Beheshti University of Medical Sciences · NCT07123181 · Data updated 2026-11-12
This project will see if eating more oregano and basil reduces inflammation and improves blood lipid and urine polyphenol levels in people who recently had unstable angina.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 75 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Shahid Beheshti University of Medical Sciences Academic / other |
| Locations | 1 site (Tehran, Tehran Province) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | September 28, 2026 |
| Study ends | October 22, 2026 |
| Registry record updated | June 16, 2026 |
| Trial ID | NCT07123181 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who recently had unstable angina, can eat oregano and basil as directed, and can attend follow-up visits at the study center are ideal candidates.
✕Probably not a fit
Patients with STEMI, those scheduled for coronary bypass grafting, people with liver cirrhosis or end-stage kidney disease, those with inflammatory or autoimmune diseases or on systemic glucocorticoids, and pregnant or breastfeeding people are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study compares standard treatment with an increased dietary intake of oregano and basil leaves in patients who recently experienced unstable angina. Participants assigned to the intervention will be instructed to consume these herbs regularly while researchers collect blood and urine samples. Primary measurements include plasma inflammatory markers, lipid factors, and total urinary polyphenol levels. Patients with recent STEMI, planned bypass surgery, advanced liver or kidney disease, active inflammatory or autoimmune conditions, or pregnancy are excluded.
Why it matters
Potential benefit: If successful, the intervention could lower inflammatory markers and improve lipid profiles, which may help reduce future cardiovascular risk.
How similar studies have gone: Epidemiological studies link higher polyphenol intake to lower cardiovascular risk, but randomized interventions specifically using oregano and basil in unstable angina are limited and largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with unstable angina Exclusion Criteria: * Patients diagnosed with STEMI * Patients undergoing coronary artery bypass grafting * Liver cirrhosis and advanced chronic kidney disease (CKD 5) * Having known inflammatory and autoimmune diseases, such as inflammatory bowel disease (IBD) and rheumatoid arthritis, or taking glucocorticoid medications * Pregnancy or breastfeeding
Where it's running
-
Imam Husain hospital
Tehran, Tehran Province, Iran Recruiting
Study contacts
- Study coordinator: Behnaz Pourrajab
- Email: behnazpourrajab@gmail.com
- Phone: +989380237111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI
This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.
-
Early Triple Lipid-Lowering Therapy After ACS
This trial tests whether adding bempedoic acid to high-intensity statin and ezetimibe within 72 hours after PCI helps more adults with acute coronary syndrome reach LDL-C goals than the standard two-drug approach.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Early single antiplatelet therapy after IVUS-guided PCI in ACS
This study tests whether stopping aspirin early and continuing a potent P2Y12 inhibitor alone is safe and effective after IVUS-guided PCI in people with acute coronary syndrome.
-
Local and systemic macrophage activation in coronary and peripheral artery disease
This study tests whether macrophage activity inside coronary and peripheral arteries relates to circulating monocyte subtypes in people with stable and acute artery disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.